Vancouver, Canada (November 4, 2016) - AbCellera announced today it has entered into a new antibody discovery partnership with a global biotechnology company.
AbCellera will use its high-throughput single-cell antibody discovery platform to perform deep screening of natural host immune repertoires to discover antibodies with defined properties. This multi-target deal takes advantage of AbCellera’s capabilities in discovering antibodies against different therapeutic targets and leverages its ability to work across species.
Through this project, AbCellera has the potential to receive downstream payments in the form of clinical milestones and royalties.
About AbCellera Biologics Inc.
AbCellera is a privately-held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single-cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans.
Media Contact
Kevin Heyries Telephone: 604.827.4151 Email:media@abcellera.com